AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform --Transaction supports development of AuraVax's lead COVID-19 intranasal program, plus other vaccines and therapeutics targeting respiratory diseases-- News provided by Share this article Share this article HOUSTON, Feb. 3, 2021 /PRNewswire/ -- AuraVax Therapeutics Inc. (www.auravax.com), a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19, today announced it has entered into an exclusive license agreement with the University of Houston (UH) with respect to the intellectual property covering a novel intranasal vaccine and STING agonist technologies. This agreement converts the optioned intellectual property between UH and AuraVax announced on October 12, 2020.